Table 2.
Human Immunodeficiency Virus Type 1 Genotype at Screening/Baseline
| Genotype Parameter | D/C/F/TAF (n = 102)a |
|---|---|
| Genotypic susceptibility | |
| Darunavir | 102 (100) |
| Emtricitabine | 100 (98) |
| Tenofovir | 102 (100) |
| All PIs | 97 (95) |
| All NRTIs | 98 (96) |
| All NNRTIs | 80 (78) |
| All INIs | 97 (95) |
| ≥1 RAM | |
| Primary PI | 5 (5) |
| Secondary PI | 100 (98) |
| Darunavir | 0 |
| Emtricitabine | 2 (2) |
| M184M/I | 1 (<1) |
| M184M/V | 1 (<1) |
| Tenofovir | 0 |
| NNRTIb | 28 (28) |
| K103N | 11 (11) |
| Primary INI | 0 |
| Secondary INI | 5 (5) |
| T97T/A | 3 (3) |
| T97A | 2 (2) |
Data are presented as no. (%).
Abbreviations: D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; INI, integrase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAM, resistance-associated mutation.
aGenotypes were not available for 7 participants due to being unable to amplify (ie, low viral load, reduced viral fitness, compromised sample collection/handling, primer incompatibility).
bIndividual NNRTI RAMs are only shown for those occurring in ≥10% of participants.